Brokerages Set $3.00 Price Target for AEterna Zentaris Inc. (AEZS)

Share on StockTwits

Shares of AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) have been given an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.

Brokerages have set a 1 year consensus price target of $3.00 for the company and are predicting that the company will post ($0.25) earnings per share for the current quarter, according to Zacks. Zacks has also assigned AEterna Zentaris an industry rank of 98 out of 257 based on the ratings given to its competitors.

Several brokerages have recently weighed in on AEZS. Zacks Investment Research upgraded AEterna Zentaris from a “hold” rating to a “buy” rating and set a $2.75 price objective for the company in a report on Tuesday. ValuEngine lowered AEterna Zentaris from a “sell” rating to a “strong sell” rating in a report on Monday, September 17th.

AEZS stock traded up $0.13 during trading on Monday, reaching $2.26. 253,654 shares of the company’s stock were exchanged, compared to its average volume of 1,186,818. AEterna Zentaris has a 1-year low of $1.12 and a 1-year high of $3.25. The firm has a market capitalization of $33.87 million, a PE ratio of -1.67 and a beta of 0.75.

AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last announced its quarterly earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.25) by $0.10. The company had revenue of $0.66 million during the quarter. AEterna Zentaris had a return on equity of 83.33% and a net margin of 34.40%. As a group, analysts predict that AEterna Zentaris will post 0.05 EPS for the current year.

About AEterna Zentaris

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications.

Further Reading: Asset Allocation, Balancing Your Investments

Get a free copy of the Zacks research report on AEterna Zentaris (AEZS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with's FREE daily email newsletter.

Leave a Reply